Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141557 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women
A Phase 2 study, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT00141557: Clinical Trial Phase 2 study, sponsored by Solvay Pharmaceuticals.
NCT00141557 is a Phase 2 study that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 133 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141557, a Phase 2 study, was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
Interventions
- DRUG esterified estrogens 1.25mg and methyltestosterone 2.5mg
- DRUG Esterified estrogens 1.25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Why NCT00141557 stopped before completion
NCT00141557 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which esterified estrogens 1.25mg and methyltestosterone 2.5mg is the first listed.
NCT00141557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00141557 about?
NCT00141557 is a clinical study titled "The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women". To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
What is the current status of trial NCT00141557?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2004-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00141557?
The interventions under investigation include: esterified estrogens 1.25mg and methyltestosterone 2.5mg (DRUG), Esterified estrogens 1.25 mg (DRUG).
Who is sponsoring clinical trial NCT00141557?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00141557's enrollment target sits among peer trials
133 538th of 2000 higher than 1,462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia